Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

Background:The transmission of drug-resistant HIV-1 can impair the virological response to antiretroviral therapy. Minority-resistant variants have been detected in acute seroconverters. We investigated the clinical relevance of the detection of majority and minority-resistant variants in an observational study in antiretroviral therapy naive, recently infected patients. Methods:We included patients infected between 1996 and 2005, with a plasma sample obtained less than 18 months after seroconversion and prior to antiretroviral therapy initiation. Majority-resistant variants were determined by direct population sequencing. Minority-resistant variants were searched by allele-specific PCR for the mutations K103N and M184V in reverse transcriptase and L90M in protease. The association between resistance and viroimmunological response to antiretroviral therapy was estimated by using a piecewise linear mixed model. Results:Majority-resistant variants were detected in 23/172 (13.4%) patients. Patients with majority-resistant variants had a lower mean plasma viral load and higher mean CD4 cell count at baseline compared with those without resistance. The decrease in viral load between 1 and 6 months on antiretroviral therapy was significantly steeper in patients with sensitive viruses compared with those with majority-resistant variants (P = 0.029). Minority-resistant variants were detected in 21/73 (29%) patients with wild-type viruses at sequencing analysis. The presence of minority-resistant variants did not modify baseline viral load and CD4 cell count and did not affect the changes in viral load and CD4 cell count. Conclusion:The transmission of majority-resistant variants, but not minority-resistant variants, influenced the response to antiretroviral therapy in this prospective study. The detection of the transmission of minority-resistant variants warrants further clinical validation.

[1]  Hélène Jacqmin-Gadda,et al.  Mixed models for longitudinal left-censored repeated measures , 2004, Comput. Methods Programs Biomed..

[2]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[4]  W. Heneine,et al.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.

[5]  Hauke Walter,et al.  Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.

[6]  Terri Wrin,et al.  The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.

[7]  D. Commenges,et al.  Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of Mycobacterium Avium Complex Infection , 2005, Antiviral therapy.

[8]  K. Metzner,et al.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.

[9]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[10]  F. Brun-Vézinet,et al.  Prevalence of HIV-1 Drug Resistance in Treated Patients: A French Nationwide Study , 2007, Journal of acquired immune deficiency syndromes.

[11]  J. Delfraissy,et al.  Prise en charge thérapeutique des personnes infectées par le VIH , 2000 .

[12]  Laura Galli,et al.  Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.

[13]  D. Pillay,et al.  Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003 , 2005, Journal of acquired immune deficiency syndromes.

[14]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[15]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[16]  Michel Roger,et al.  High rates of forward transmission events after acute/early HIV-1 infection. , 2007, The Journal of infectious diseases.

[17]  Mark A Wainburg.  The impact of the M184V substitution on drug resistance and viral fitness , 2004 .

[18]  M. Wainberg.  The impact of the M184V substitution on drug resistance and viral fitness. , 2004, Expert review of anti-infective therapy.

[19]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.